Page 120 - Binder2

The science is real. The pieces are here.
What’s missing is a system willing to prioritize
compatibility over velocity. A system willing to build
therapies that last—even if they take longer to get to
market.
A system willing to shift the question from “How do we
deliver this drug?” to “How do we teach the immune
system to live with it?”

Because once we design biologics for immune
cooperation, tolerization is no longer a foregone
conclusion.
It becomes a solvable challenge.
A design flaw.
A preventable failure in a future built on precision.

And in that future, durability isn’t the exception.
It’s the standard.

Durable biologics aren’t just better for patients.
They’re better for payers, for regulators, and for the long-
term credibility of the industry itself.

And if we want to rebuild trust in biologics, there is no
better way to start than by building therapies that last.

3.4 – Technology Platforms That Are
Already Doing This

This isn’t speculative.

The idea that biologics can be designed for immune
compatibility—not just potency—is already being tested.

118